UNITED STATES SECURITIES AND EXCHANGE COMMISSION

2 October 2009

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933

Emergent BioSolutions Inc.

File No. 333-136622 -- CF# 23967

Emergent BioSolutions Inc. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 filed on August 14, 2006, as amended.

Based on representations by Emergent BioSolutions Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.11	through August 14, 2012
Exhibit 10.12	through August 14, 2012
Exhibit 10.13	through August 14, 2012
Exhibit 10.14	through August 14, 2012
Exhibit 10.15	through August 14, 2012
Exhibit 10.43	through October 20, 2012

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Timothy S. Levenberg Special Counsel